Biosimilars in Retina Care

This expanding category of drugs can make a global impact on retinal disease.

By: Ashish Sharma, MD

Ophthalmology Management March 1, 2026 Vol 30, Issue Retina 2026

Clinical Report: Biosimilars in Retina Care

Overview

Biosimilars are emerging as a significant advancement in the treatment of retinal diseases, particularly in enhancing access to anti-VEGF therapies. Their integration into clinical practice is essential for addressing the cost burdens associated with long-term treatment.

Background

The advent of anti-VEGF therapy has revolutionized the management of retinal diseases, allowing for vision preservation and improvement in patients with conditions like neovascular age-related macular degeneration and diabetic macular edema. However, the chronic nature of these conditions necessitates repeated treatments, which can strain healthcare resources, especially in low-income settings. Biosimilars present a promising solution to improve access and reduce costs while maintaining treatment efficacy.

Data Highlights

No specific numerical data provided in the article.

Key Findings

Biosimilars are not simply generic versions of biologics; they undergo a rigorous process to demonstrate similarity in structure, function, efficacy, safety, and immunogenicity.
Global regulatory agencies have aligned on the principles for biosimilar approval, emphasizing a totality of evidence approach.
Ranibizumab biosimilars are the most established class, with multiple approvals across various regions.
Lower costs associated with biosimilars have led to increased patient access and reduced undertreatment in several regions.
Clinical trials have shown that biosimilars achieve noninferior visual outcomes compared to reference agents.

Clinical Implications

Healthcare professionals should consider the integration of biosimilars into treatment regimens to enhance patient access to necessary therapies while managing costs. Continuous monitoring and evaluation of biosimilars in clinical practice are essential as more data becomes available.

Conclusion

Biosimilars represent a significant advancement in retinal care, offering a viable alternative to traditional anti-VEGF therapies while addressing cost and access challenges. Their responsible integration into clinical practice is crucial for optimizing patient outcomes.

PentaVision

Ophthalmology Management